Your browser doesn't support javascript.
loading
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Guièze, Romain; Liu, Vivian M; Rosebrock, Daniel; Jourdain, Alexis A; Hernández-Sánchez, María; Martinez Zurita, Aina; Sun, Jing; Ten Hacken, Elisa; Baranowski, Kaitlyn; Thompson, Philip A; Heo, Jin-Mi; Cartun, Zachary; Aygün, Ozan; Iorgulescu, J Bryan; Zhang, Wandi; Notarangelo, Giulia; Livitz, Dimitri; Li, Shuqiang; Davids, Matthew S; Biran, Anat; Fernandes, Stacey M; Brown, Jennifer R; Lako, Ana; Ciantra, Zoe B; Lawlor, Matthew A; Keskin, Derin B; Udeshi, Namrata D; Wierda, William G; Livak, Kenneth J; Letai, Anthony G; Neuberg, Donna; Harper, J Wade; Carr, Steven A; Piccioni, Federica; Ott, Christopher J; Leshchiner, Ignaty; Johannessen, Cory M; Doench, John; Mootha, Vamsi K; Getz, Gad; Wu, Catherine J.
Affiliation
  • Guièze R; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, Fr
  • Liu VM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Rosebrock D; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Jourdain AA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Hernández-Sánchez M; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca, 37007 Salamanca, Spain; Servicio de Hemat
  • Martinez Zurita A; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Sun J; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Ten Hacken E; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Baranowski K; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
  • Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Heo JM; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA.
  • Cartun Z; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
  • Aygün O; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Zhang W; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
  • Notarangelo G; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Livitz D; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Li S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Biran A; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
  • Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
  • Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospita
  • Lako A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Ciantra ZB; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Lawlor MA; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.
  • Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Udeshi ND; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA.
  • Letai AG; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Neuberg D; Harvard Medical School, Boston, MA 02215, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Harper JW; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA.
  • Carr SA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Piccioni F; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Ott CJ; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.
  • Leshchiner I; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Johannessen CM; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Doench J; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Mootha VK; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Getz G; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA.
  • Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospita
Cancer Cell ; 36(4): 369-384.e13, 2019 10 14.
Article in En | MEDLINE | ID: mdl-31543463
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Bridged Bicyclo Compounds, Heterocyclic / Proto-Oncogene Proteins c-bcl-2 / Mitochondria Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2019 Type: Article Affiliation country: France
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Bridged Bicyclo Compounds, Heterocyclic / Proto-Oncogene Proteins c-bcl-2 / Mitochondria Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2019 Type: Article Affiliation country: France